What is Anavex Life Sciences Corp. (AVXL)?

Anavex Life Sciences Corp. (AVXL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AVXL?

The current price of AVXL is $1.31. Prices are updated in real time on Stocks360.

What is AVXL's price-to-earnings (PE) ratio?

AVXL's trailing twelve-month PE ratio is -5.01, based on current price and earnings per share data available on Stocks360.

What is AVXL's market capitalization?

AVXL's market capitalization is $121,432,863.00, placing it in the small-cap tier.

Anavex Life Sciences Corp. (AVXL)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.31

Market Cap

$121.43M

PE (TTM)

-5.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.17

Day Range

$1.25 – $1.32

52-wk Range

$1.14 – $8.45

Avg Volume

N/A

Volume

1.35M

Anavex Life Sciences Corp. (AVXL) is a publicly traded company in the Healthcare sector. Latest price: $1.31. Market cap $121.43M. Trailing PE -5.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 28, 2026

EPS $-0.03 vs est. $-0.08

Beat by $0.05

Next Earnings

Nov 24, 2026

EPS estimate $-0.11

Proprietary Signals

Signal snapshot temporarily unavailable.

About Anavex Life Sciences Corp.

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating pro…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-5.01×
P/S (TTM)	0.00×
P/B	1.07×
P/FCF (TTM)	-3.60×
EV / EBITDA	-0.14×
EV / Sales	0.00×
Earnings Yield	-20.07%
Free Cash Flow Yield	-27.78%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.11M
Net Income (TTM)	-$24.37M
Free Cash Flow (TTM)	-$33.73M
Net Debt	-$118.33M
Working Capital	$112.45M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-21.11%
Return on Invested Capital	-27.25%